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ABSTRACT 
 
This thesis examined the factors correlated with rapid and benign progression of disease in 
a group of 1452 Parkinson’s disease (PD) patients.  The data were collected in a movement 
disorders clinic at the Royal University Hospital, University of Saskatchewan run by Dr. 
Alex Rajput and Dr. Ali Rajput.  This data is a clinical dataset of PD patients collected 
from 1970 through to February, 2005.  This was a retrospective cases-only study, with 
anticipated analytical follow-up if any correlations were detected between progression type 
of PD and the many independent variables available in the dataset. 
 
Rapid progression was defined as those subjects who reached Hoehn and Yahr stage 3 
within three years or H&Y stage 4 or 5 within five years.  Subjects who remained in Hoehn 
and Yahr stage 1 or 2, ten years after onset of disease, were defined as having benign 
progression.  The study analyzed demographic and clinical findings at first visit to this 
clinic associated with rapid and benign progression of PD.   
 
Analysis revealed that, at first clinic visit, benign progression was positively associated with 
disease duration (OR=1.41; 95% CI 1.27, 1.57), male sex (OR=3.23; 95% CI 1.70, 6.16), 
and current smoking habit (OR=2.33; 95% CI 0.67, 8.11).  Benign progression was 
negatively associated with older age of onset (OR=0.36; 95% CI 0.25, 0.50), past history of 
smoking (OR=0.46; 95% CI 0.24, 0.89), current or past use of levodopa (OR=0.45; 95% 
CI 0.21, 0.98), and mild to severe rigidity (OR=0.43; 95% CI 0.23, 0.80).   
 
Analysis also revealed that, at first clinic visit, rapid progression was positively associated 
with older age of onset (OR=2.45; 95% CI 1.80, 3.33) and mild to severe rigidity 
(OR=1.73; 95% CI 1.02, 2.94).  Rapid progression was negatively associated with disease 
duration (OR=0.52; 95% CI 0.44, 0.62), male sex (OR=0.58; CI 0.35, 0.95), and mild to 
severe resting tremor (OR=0.47; CI 0.28, 0.77).    
 
The results of this study indicate that age of onset, disease duration, male sex, and rigidity 
are good potential predictors of disease progression in PD because they have opposite 
associations with rapid and benign progression.  History of levodopa use was negatively 
associated with benign progression and as such may be good indicator of non-benign 
progression.  Although previous studies found no predictive value for smoking history, the 
current study reported a unique association between smoking history and benign 
progression.  Past smoking history was negatively associated with benign progression.  
While there was a positive association with current smoking history, the result was not 
statistically significant.  Resting tremor was negatively associated with rapid progression 
and as such may be a good indicator of non-rapid progression. 
 
Disease characteristics collected at first clinic visit are useful in predicting the course of 
progression of PD.  With more rapid progression of PD closer and more frequent follow-
up of patients may be necessary.    
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Chapter 1 
Introduction 
 1.1 Rat ionale  o f  the Study 
Parkinson’s disease (PD) exhibits heterogeneity of progression which can influence clinical 
treatment and follow-up patterns.  The detection of clinical features and characteristics 
correlated with more rapid progression of PD can help identify patients who may benefit 
from closer and more frequent clinical follow-up.  Furthermore, the detection of clinical 
features and characteristics correlated with benign progression of PD can aid identification 
of patients who require less frequent clinical follow-up.  Taken together these findings can 
support more specific medical care based on the speed with which PD progresses.   
 
PD is a progressive, neurodegenerative disorder of unknown etiology 1,2 that generates the 
characteristic symptoms of bradykinesia, resting tremor, rigidity, and postural instability.1  
This loss of nerve cells occurs primarily in the presynaptic dopaminergic cells of the 
substantia nigra, with concomitant loss of dopamine neurotransmitter in the corpus 
striatum.3  Degeneration of this nigrostriatal pathway decreases signal transduction to the 
motor cortex and thus diminishes fine tuning of motor movement.3   
 
PD progresses at different rates in different patients.4,5  A definitive profile of the 
characteristics of rapid and benign progression can help specify medical interventions and 
the frequency of clinical follow-up.  There have been many Canadian and Saskatchewan 
studies concerning various aspects of PD, but minimal focus on progression.   
 
This current Saskatchewan study was unique for several reasons.  First, the database 
included 1648 Parkinsonism (PS) patients who came from all over Saskatchewan for 
treatment in one Movement Disorders clinic.  Second, the database was a longitudinal 
collection of patient information from 1970 to February 2005.  Third, patients were 
assessed, diagnosed, and treated by only one of two neurologists.  The definitive diagnosis 
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of PD is obtained on post-mortem neuropathologic examination,6,7 but because so few 
patients in this database received that definitive diagnosis, a clinical diagnosis of PD was 
used for this study.  The clinical diagnosis of PD rests on the clinical presence of two out 
of three symptoms of bradykinesia, resting tremor, and rigidity.8  It is generally accepted 
that clinical diagnosis be performed by a neurologist with experience in movement 
disorders and an interest in PD.9  These criteria were more than adequately met with this 
database. 
 
 1.2 Purpose  o f  the  Study 
PD is a significant health issue that currently has no cure.  The per capita direct economic 
burden was determined, in one U.S. study, to be $6000.00 USD per year, while the hidden 
costs borne by families, such as lost wages and informal care, was triple the direct cost.10  A 
recent study of costs associated with PD, for the province of Ontario between 1993 and 
1999, reported that costs for services in several areas were significantly higher.11  The study, 
which compared costs for PD patients with age-matched controls, detailed that average 
annual cost of physician services were 1.4 times higher, there were 1.45 times more acute 
hospitalizations and number of patients admitted, the length of hospital stays were 1.19 
times greater, and the average annual drug costs were 3.02 times greater.11  Those with PD 
experience a significant deterioration in health related quality of life (QoL) with advancing 
disease predominantly associated with deterioration of mobility, activities of daily living, 
physical and social function, and self-care.12  This deterioration in QoL results from disease 
progression, not the normal aging process.12   These studies point to the fact that, when 
progression of PD is more rapid, deterioration in QoL and the burden of disease will be 
more immediate and more profound.   
 
The primary interest of this study was to ascertain those factors and clinical features, 
present at the initial visit to a clinician, associated with rate of progression of PD.  The 
identification of how rapidly PD will progress will facilitate the equitable administration of 
treatment and clinical follow-up.   
 
 1.3 Research Obje c t i ve s  
The general research objectives of this study were as follows: 
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 1.  To determine the characteristics of the study population at their first visit. 
2.  To determine the correlates of benign progression in PD. 
3.  To determine the correlates of rapid progression in PD 
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CHAPTER 2 
Literature Review 
 
 2.1 Parkinson ism and Parkinson ’s Disease  
Parkinsonism (PS) is a neurological syndrome caused by many diseases and conditions.  PS 
encompasses Idiopathic Parkinson’s Disease (IPD), atypical Parkinsonism such as Multiple 
System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP), pseudoparkinsonism 
where Parkinsonian signs are associated with other diseases, symptomatic parkinsonism 
where Parkinsonian symptoms manifest from insults such as drug abuse, and inherited 
forms of PD.13   The task faced by the neurologist is to differentiate IPD from the other 
less common forms of PS.  IPD is the most common form of PS representing 42 to 69 
percent of all cases.14  The reported relative frequency of IPD varies from study to study 
and depends upon how the various forms of PS are identified and evaluated.2,14  For the 
remainder of this paper the use of PD will infer IPD unless otherwise indicated.   
 
There are three commonly used levels of diagnosis: possible, probable and definitive.   A 
diagnosis of possible PD requires the presence of two of the four cardinal features of 
tremor, bradykinesia, rigidity, and postural instability.  These symptoms generally begin 
unilaterally (on one side of the body) in most PD patients.14,15  There is also a marked and 
sustained response to either levodopa or dopamine agonist pharmacology.13,14  A probable 
diagnosis of PD requires the presence of three of the four cardinal features, which have 
been present for at least three years, and a sustained response to Levodopa or dopamine 
agonist.14,15  Definitive diagnosis requires postmortem pathologic confirmation of neuronal 
loss in the substantia nigra along with the presence of Lewy bodies in any surviving nigral 
neurons.15  A detailed discussion of the pathophysiology of PD is in section 2.3 below.  
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 2.2 Appli cable  Neurophys io logy  
Normal voluntary movement involves several areas of the brain.  First, the thought of 
movement manifests in the frontal lobe from which signals are sent to the pre-motor 
cortex for sequence planning of the desired movement.  Signals then pass to the motor 
cortex where specific muscle commands are executed.  Output signals from the striatum, 
one of the basal ganglia, connect to the thalamus, which in turn connect to the motor 
cortex.16  This feedback is responsible for fine tuning so that the enacted movement is 
fluid.  The striatum receives input from several areas of the brain.  Some of this input 
stimulates the striatal neurons to fire, while input from the substantia nigra, another basal 
ganglia, inhibits striatal neurons from firing.  The neural tract that runs from the substantia 
nigra to the striatum, called the nigrostriatal pathway, consists of dopaminergic neurons.16  
These neurons have dopamine as a neurotransmitter.  When stimulated to fire a signal, the 
dopaminergic neurons release dopamine in the target area of the striatum.  The dopamine 
binds to specific dopamine receptors which in turn inhibit striatal neurons from firing.   
 
2.3 The Pathophys io logy  o f  Parkinson ’s  Disease  
PD is a neurodegenerative disorder.  Postmortem autopsy of PD reveals a decreased 
presence of pigmentation in the substantia nigra.  This correlates with a loss of 
dopaminergic neurons.  The rate of degeneration is eight to ten times higher than in 
healthy age-matched controls.17  Some surviving neurons have eosinophilic cytoplasmic 
inclusions called Lewy bodies, which are glassy or translucent in appearance.  Due to this 
dopaminergic neuronal loss there is decreased dopamine release in the striatum and 
subsequent decreased signal transduction to the motor cortex.  This leads to diminished 
fine tuning of voluntary motor movement that manifests the cardinal symptoms of PD. 
The cardinal symptoms are: tremor while at rest, bradykinesia or slowed voluntary 
movements, rigidity or stiffness with passive movement of limbs, and postural instability 
that increases the likelihood of falls.3  In the early stages of disease the symptoms appear 
on one side of the body and pathologically there is degeneration of the substantia nigra on 
the opposite side (contralateral) to the symptoms.   
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 2.4 Epidemio logy  o f  Parkinson ’s  Disease  
  2.4.1 Prevalence 
Prevalence studies of PD have been conducted since the 1950’s with variation in reported 
prevalence ranging from as low as 18 to as high as 244 per 100,000 population.1,2  A recent 
review reported a variation in age-adjusted prevalence from 104.7 to 258.8 per 100,000 
population.18  These figures vary from study to study, and place to place, and by 
methodology.  Another review of worldwide occurrence of PD revealed a 13 fold 
difference in prevalence between the highest (Uruguay) and lowest (China) in survey 
studies, and a three fold difference between the highest (Iceland) and the lowest (Libya) for 
prevalence studies using clinical or administrative data sources.19  Although some of this 
wide variation in prevalence can be attributed to differences in methodology, some of the 
variation could result from differences in diagnostic criteria and how cases are 
ascertained.18  Use of administrative and clinical data sources, while relatively cost effective, 
underestimate prevalence and incidence rates.  On the other hand, door-to-door surveys 
provide more accurate results, but at a high financial cost.1,18  Recent Canadian figures 
show that, during the period from 1991 to 1999, age-adjusted prevalence has increased 
from 3.54 to 3.73 per 1,000 population for men and increased from 3.18 to 3.49 per 1,000 
population for women.11  The western provinces have the highest prevalence rates in 
Canada.19,20,21  Two separate studies reported that Saskatchewan had the highest prevalence 
rate of PD of any Canadian province.19,21  One study, that used hospital separation data 
from 1976 to 1995, found the highest prevalence of PD in Saskatchewan, 23.5 and 16.4 per 
100,000 population for men and women respectively.19  This was about 1.5 times the 
national average for both sexes.19  It is evident that PD has a significant and increasing 
prevalence in Saskatchewan. 
 
The temporal variation, or the change in frequency of PD over time, reveals that over the 
past 20 years the mean age of death has increased by 5 years, as a direct result of improved 
pharmacological treatment.2  Given that the majority of persons affected by PD are in 
older age groups and that there is an expected six fold increase in the size of this group 
over the next 50 years,9 the social and familial burden of PD will become profound. 
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  2.4.2 Incidence 
Different systematic reviews have reported considerable variation in the estimated crude 
incidence rates of PD from as low as 4 to as high as 25 per 100,000 population.1,2,22  One of 
these systematic reviews reported that the best incidence studies yielded an approximate 
incidence rate of 17 per 100,000 per year.22  Yet another recent review reported an average 
age-adjusted incidence rate of 14 per 100,000 person-years for several US studies.18  Most 
incidence studies ascertain data from treatment settings or administrative data sources.  
The drawback of these sources is they underestimate incidence by omitting individuals who 
do not seek medical attention.23  Studies that used a two study survey method reported 
higher incidence rates than other methods.23,24  What these different studies do show is that 
incidence of PD increases sharply after the age of fifty and generally peaks between 70 and 
79 years of age.22,25  Studies that were able to include the very old reported a doubling of 
incidence per year between the 70-79 age group and the 80-84 age group.22,24   
 
Incidence of PD was reported to be 1.5 to 2.0 times higher among men than women for all 
age groups.24,25,26,27,28  The low frequency of PD and the difficulty in establishing a proper 
diagnosis are the two main challenges that consistently underestimate both incidence and 
prevalence.  One US study used incident cases from the Olmstead County PD study from 
1976 to 1990 as the numerator, and US census data from the same period of time to 
calculate the denominator in terms of person-years, for calculating age adjusted incidence 
rates.26  Person-years is defined as the sum of the periods of study time for each of the 
subjects.  This study reported that while the total incidence over the life course for men 
was 13.03 per 100,000 person-years, the incidence peaked in the 75-79 age group at 182.46 
per 100,000 person-years.  Incidence rates for women, on the other hand, peaked in the 80-
99 age group at 72.91 per 100,000 person-years and had a total rate over the life course of 
8.76 per 100,000 person-years.26  This study demonstrated that men have a higher 
incidence rate of PD and that their peak level occurs in a younger age group than women. 
 
  2.4.3 Mortality 
A 1967 Hoehn and Yahr clinical study on PD reported a standardized mortality ratio 
(SMR) of 2.9,4 while a population-based study conducted about the same time, reported a 
SMR of 1.6.29  After the introduction of levodopa therapy there was an initial significant 
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decrease in mortality followed by an increase well above the pre-levodopa levels.  The SMR 
has since returned to those levels observed before the introduction of levodopa.30  
Regardless of the type of study, it has been shown that despite improved morbidity with 
levodopa therapy, those with PD have a shorter life expectancy than the general 
population.18,30,31  It has been suggested that this compromised life expectancy stems from 
two potential causes.  First, severe motor dysfunction in the advanced stages of PD may 
lead to increased likelihood of falls.30  Second, end-stage immobility could increase the risk 
of fatal infections.31   
 
However, there is considerable variation in the reported SMR’s of these studies.  Some 
studies have reported SMR close to pre-levodopa levels between 2.3 and 4.1.30,32   Yet other 
studies report a moderately increased SMR between 1.58 and 1.7.26,31,33,34  SMR increases 
with age and is higher in males than in females.19,26,31  A Canadian study revealed an 
absolute mortality rate of 3.4 per 100,000 and illustrated an increase in this rate over the 
study period of 1977 to 1996.19  This study also showed that mortality rate increased with 
age and did not reach a peak, and also revealed that the mortality rate for males was higher 
than females.19  An Ontario study revealed a significantly higher mortality rate of 2.5 for 
PD patients compared to controls.35  Methodological differences can account for these 
reported variations in SMR.  Use of death certificates can yield inaccurate results due to 
inconsistent identification of PD as a cause of death.  Use of clinical data can under- or 
over-estimate SMR depending on the type of study population.31  A more recent 
population based study reported a moderately elevated SMR for PD at 1.32.  This study 
purported that its methodology identified only clinically defined PD and as such reflected a 
more accurate SMR.31   
 
 2.5 Risk Factors  for Parkinson ’s Disease  
  2.5.1 Age and Age of Onset 
Although there is considerable variation in the absolute prevalence of PD, the incidence 
and risk of the disease is directly proportional to increasing age.1,18  Incidence varies with 
age for both men and women and begins to rise after 50 years of age.25  A variety of 
different categorical definitions of age of onset have been used.36, 37, 38, 39  Onset under the 
age of 40 characterizes Early Onset Parkinson’s Disease (EPD), which represents about 3-
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10% of all PD.39,40  By contrast, the average age of onset of Older Onset Parkinson’s 
Disease (OPD) is above 70 years of age.36,37  
 
It has been reported that those with EPD were more likely exposed to rural living 
environment and to have used well water while growing up.39,40  At the same disease 
duration of about 5 years, greater motor impairment was reported in OPD than EPD.36,37,38  
EPD patients experienced a longer duration of disease, were treated with a higher daily 
dose of levodopa for a longer period of time, and more frequently experienced levodopa 
induced dyskinesias, but had less frequent occurrence of psychotic symptoms.37,41  Those 
with EPD however, experienced a slower initial disease progression as evidenced by the 
significantly longer period of time before commencing levodopa treatment.36,41,42  Further 
evidence of slower initial disease progression in EPD is evident in decreased occurrence of 
bradykinesia, disability, and mortality.43  It was also noted that those with EPD had fewer 
co-morbid conditions.36  Thus, earlier age of onset is associated with slower progression of 
disease and less impairment of motor function.    
 
There are several explanations for the different evolutions of PD related to age of onset.  
First, EPD and OPD could be etiologically different as evidenced by the strong genetic 
component to EPD compared to OPD.43  Second, differences in the severity of neuronal 
damage reflect differential progression in EPD and OPD.43  Thus, EPD could have a more 
selective dopamine deficiency due to environmental or occupational exposures that 
manifest specific neuronal damage.37,39  OPD, on the other hand, could be the result of 
non-selective atrophy involving neurotransmitter systems other than the nigrostriatal 
system.37  It has been suggested that these age differences could result from an age-related 
neuronal vulnerability or a time-dependent causal mechanism.1   
 
  2.5.2 Sex Differences 
Although earlier prevalence studies demonstrated no significant male/ female 
differences,44,45 a higher percentage of studies now demonstrate that men have a slightly 
higher age-adjusted prevalence and incidence of PD.1,18,25,46,47  The higher prevalence of PD 
in males is persistent across race.1  These sex differences could be the result of differences 
in environmental and/or occupational exposures.18  There could also be a sex-linked 
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genetic predisposition, or sex hormones could confer differences in susceptibility to risk.18  
The ratio of males to females ranges from 0.8, as seen in Japanese studies, to as high as 3.7 
in some areas of China.1,18  It has been suggested that the Japanese results may be an 
artifact, or may be related to the longer survival rate of Japanese women.18   
 
The age of diagnosis of PD is similar for men and women and they experience similar 
symptoms at onset.   As the disease progresses the number of reported symptoms increases 
and sex differences in symptom profile emerge.48  Men develop more severe Parkinsonian 
motor symptoms despite higher doses of levodopa treatment, while women develop more 
levodopa-induced dyskinesias.48,49  It has been suggested that PD progresses more rapidly 
in men, but the exact reason for this has not been determined.49  However, some 
investigators suggest that PD may be more malignant in men and progress more rapidly.  
Men may also have less than optimal response to levodopa therapy.50  Other studies have 
suggested a possible protective role for estrogen.49 
 
  2.5.3 Lifestyle Risk Factors 
Many epidemiological studies have been conducted on cigarette smoking as a risk factor 
for PD.  Two systematic reviews of this literature revealed that never smokers are twice as 
likely to develop PD as smokers.51,52  Although the incidence of PD rises sharply with age 
in both sexes, smoking was associated with a lower incidence in both sexes and in all age 
groups.27,53  A recent systematic review of 48 case-control and cohort studies reported that 
the pooled relative risk versus never smokers was 0.39 for current smokers and 0.80 for 
past smokers.54  The protective effect increases in a dose-dependent manner as the number 
of cigarette-pack-years increases.18,55  A study by Gorell et al. showed that moderate 
smokers had an OR of 0.7 while heavy smokers had an OR of 0.43 when both were 
compared with those who had never smoked.56  It has been suggested that the observed 
protective effect may actually result from behavioural and/or environmental factor(s) 
associated with smoking, such as coffee drinking, while others have suggested that having 
PD itself leads to reduced smoking behaviour.57   
 
Case-control studies 58,59,60 and prospective studies 53,61,62 have found a strong inverse 
association between both coffee drinking and caffeine intake and the incidence of PD.  
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Ross et. al. found that this strong inverse association was independent of smoking.62  The 
Ascherio et al. study evaluated gender differences in the effect of coffee consumption, 
caffeine intake, and smoking habit on the incidence of PD.61  For men there was a strong 
inverse association between coffee consumption and caffeine intake for both never and 
ever smokers.  For women there was a U-shaped association between coffee consumption 
and risk of PD with the lowest risk at 1-3 cups of coffee per day.  Analysis of total caffeine 
intake per day revealed similar findings to coffee consumption.61  These results 
demonstrate a protective effect for chronic consumption of moderate amounts of 
caffeine.61  A systematic review of 13 studies revealed that the pooled relative risk for 
coffee drinkers was 0.69 when compared to non-coffee drinkers.54   
 
Investigations of the association between dietary factors and PD have had inconsistent 
results.  Some studies have found a protective effect for the consumption of antioxidant 
food and supplements,63 while others have demonstrated no such association.64  Conflicting 
findings have also demonstrated that a diet high in dietary fat can either increase the risk of 
PD, 64 or have no impact on risk.58  In a case-control study by Fall et al. several dietary 
items containing niacin, including coffee, were reported to have a protective effect.58  Some 
authors have suggested that the geographic variability of the prevalence of PD is a function 
of these lifestyle risk factors.65,66   
 
  2.5.4 Occupational Risk Factors 
There have been several studies conducted on the long-term exposure to specific and 
combinations of transition metals because of their accumulation in the substantia nigra of 
PD patients and their involvement in oxidative reactions.67  Lai et. al. reviewed eight studies 
on the relationship between metal exposure and the development of PD and found that 
while some studies revealed a positive association between PD and exposure to metals 
such as mercury, lead, manganese, copper, and iron, other studies showed no such 
association.66  Two separate studies, also reviewed by Lai et al. additionally revealed that 
long-term exposure to combinations of metals was associated with PD.66  Overall the 
epidemiological evidence of the association between long-term metal exposure and PD is 
inconclusive.66,67   
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The majority of studies that investigated the association between pesticide exposure and 
PD reported a positive association with a variation in OR of 1.02 to 7.0.66,67  Two of the 
earlier studies reviewed by Lai et. al. showed no association.66  A meta-analysis of 19 studies 
by Priyadarshi et. al. calculated the combined OR at 1.94.68  Some of these studies, as 
reviewed by Lai et. al., found a positive correlation between PD and duration of pesticide 
exposure.66  Despite these conclusions the high variability between the odds ratios of the 
different studies suggests the associations are not definitive and more detailed study of 
pesticide exposure is required.66,67  
  
Rural living, farming, and well water drinking are all positively associated with PD.66  Half 
of the 22 studies reviewed by Lai et al. reported a statistically significant increased risk of 
PD associated with these conditions.66  Rural living, farming, and drinking well water may 
be surrogates for pesticide exposure by use,69 or leaching into the soil and ground water.70  
More recent studies report greater occurrence of PD in the rural population with age-
adjusted prevalence 1.2 to 1.5 fold higher than in the urban population.46  Canadian studies 
have also found a higher prevalence in the rural population.20,39 
 
  2.5.5 Multi-Factorial Models 
Various studies suggest that most cases of PD have multi-factorial etiologies consisting of 
both genetic and environmental components.57,71,72,73,74,75  The specific models produced by 
the respective studies reveal differences in risk factors and protective factors.  Some of 
these differences are related to the specifics of the study, such as the type of metal subjects 
may have been exposed to during their lives, or the specific amount of cigarette-pack-years 
that define categories of smoking.  The specific geographic location of the study also plays 
a role in the characteristics of the model proposed.  A study in Taiwan is inherently 
different than a Canadian study.  Reducing to a common denominator it can be deduced 
that smoking remains a protective factor, in the majority of studies.71,74,75  Risk factors can 
be generalized.  One risk factor appears to be exposure to pesticides, either through direct 
exposure in specific occupations such as farming, or indirectly as an environmental toxin in 
well water, for example.  Another risk factor appears to be familial history of PD.  Some of 
these studies also investigated other possible risk factors such as medical history and 
psychiatric history, the results of which were inconsistent.73,74  Thus, the specific 
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environmental and genetic factors that interact in determining risk of PD require further 
and more detailed study.   
 
 2.6  Pharmacologi cal  Treatment  
Levodopa is the treatment of choice for patients with PD.  The majority of 
pharmacological treatments in PD are symptomatic, which reduce the severity of 
symptoms.76  Drugs may also be classified by their protective effect where disease 
progression is slowed, stopped, or reversed.76  Recent investigations have focused on the 
potential protective effects of selegiline and rasagiline. Although both of these drugs are 
selective MAO-B inhibitors, it is believed that their mechanism of neuroprotection is 
multi-factorial.77  Other clinical investigations demonstrated that selegiline and rasagiline, in 
untreated PD patients, delayed the average time before patients must begin levodopa 
therapy.77,78,79  Selegiline and rasagiline have also been shown to decrease the rate of 
progression of PD.78,79,80,81  A study by Diederich et al reported that less aggressive 
treatment strategies were used with OPD patients, where levodopa mono-therapies were 
preferred over combined therapies.36  Although levodopa is the treatment of choice, other 
anti-Parkinson medications such as MAO-B inhibitors can be used to potentially delay its 
inevitable use.   
 
 2.7 Progress ion o f  Disease  
  2.7.1 Tools to Predict Progression 
There are three tools for predicting progression of PD.  First, there are neuro-imaging 
techniques like Positron Emission Tomography (PET) and Single Photon Emission 
Computerized Tomography (SPECT) that monitor changes in Fluorodopa (F-Dopa) 
uptake and Dopamine type 2 (D2) receptor binding respectively.82  These neuro-imaging 
techniques measure dopaminergic dysfunction and it has been shown that functional 
neurological decline correlates well with clinical measures of progression.82,83,84  Neuro-
imaging techniques are not typically used in a clinical setting and clinicians are limited by 
the frequency of follow-up visits to track changes in functionality.82  There is also a 
significant cost associated with the use of neuro-imaging techniques.  As such, previous 
studies used small samples sizes and generally had short-term follow-up periods.83,84,85  
Neuro-imaging information was not available in the database used for the current study.   
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The second tool for predicting progression is genetic research.  About 10-24% of those 
with PD have a family history of the disease.86  Both autosomal dominant and autosomal 
recessive modes of transmission have been identified, some of which have a phenotype 
similar to PD.87,88  Since the occurrence of genetic forms of PD is relatively low and since 
the database used in this study did not have genetic information, the usefulness of genetic 
research to predict progression of disease for this current study is limited.   
 
The third tool for predicting progression is the use of clinical indicators.  There are several 
clinical rating scales that almost exclusively focus on motor impairment as it relates to 
deterioration in the cardinal clinical features of PD.89  Another commonly used scale is the 
Unified Parkinson’s Disease Rating Scale (UPDRS), a multi-modular, four part scale that 
evaluates mentation, ADL, motor functioning, and complications of therapy.89  Although 
this scale provides a more complete assessment of patients, it is time consuming to 
complete and is usually reserved for specific investigations rather than everyday clinical use.   
 
The Hoehn and Yahr Scale of Global Disability (H&Y) was introduced in 1967 and 
remains the most ubiquitous rating scale in assessment of PD.4,90  The H&Y is a five point, 
non-linear or ordinal scale that estimates the clinical functioning of PD patients using both 
impairment (objective signs) and disability (functional deficit) of movement, balance, and 
gait.4,90  The scale focuses on milestones of disease and as such reflects progression of 
disease from unilateral to bilateral limb involvement, then to loss of postural reflexes, and 
finally to loss of independent mobility.89   Since the vast majority of subjects in the database 
used in the current study had H&Y scores, this study used this clinical rating scale as a tool 
for assessing progression of PD.  During the 1990’s some neurologists began to use a 
modified H&Y scale that added two 0.5 increments between stages 1 and 2 and stages 2 
and 3.90  The original and modified scales are presented in Table 2.1 below.90 
 
The Movement Disorders clinic in Saskatoon began using the modified H&Y scale in the 
1990’s.  For the purposes of this investigation any modified H&Y scores were converted to 
original scores where 1.5 was counted as a 1 and 2.5 was counted as a 2 on the original 
H&Y scale.  The logic behind this decision was two fold.  First, the modified 1.5 is not a 2 
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on the original scale because there is no bilateral involvement of the disease and the 
modified 2.5 is not a 3 on the original scale because postural instability is not yet present.  
Second, far more patients in this database were assessed using the original scale than the 
modified scale. 
 
Table 2.1  Comparison of Original and Modified Hoehn and Yahr Scales 
Hoehn and Yahr Scale  Modi f i ed Hoehn and Yahr Scale  
1: Unilateral involvement only; usually with minimal 
or no functional disability 
1.0: Unilateral involvement only 
 1.5: Unilateral and axial involvement 
2: Bilateral or midline involvement without 
impairment of balance 
2.0: Bilateral involvement without impairment of 
balance  
 2.5: Mild bilateral disease with recovery on pull 
test 
3: Bilateral disease: mild to moderate disability with 
impaired postural reflexes; physically independent 
3.0: Mild to moderate bilateral disease; some 
postural instability; physically independent 
4: Severely disabling disease; still able to walk or 
stand unassisted 
4.0: Severe disability; still able to walk or stand 
unassisted 
5: Confinement to bed or wheelchair unless aided 5.0: Wheelchair bound or bedridden unless aided 
 
 
  2.7.2 Defining Progression of PD 
In their 1967 study, Hoehn and Yahr identified 20 of 183 subjects who were still in either 
H&Y stage 1 or 2 after having had PD for ten years.4  This slow progression of disease is 
now commonly identified as benign progression.  Subsequent studies also identified small 
groups of patients with benign progression.  Marttila and Rinne reported that ten percent 
of their study population had benign progression.5,91  Hely et al also reported 13 of 136 
subjects with benign progression.34  The most recent publication of their Sydney Multi-
center Study revealed that 12 of the 13 patients with benign progression were still alive 
after 15 years, 4 of which were still at H&Y stage 2, while the remainder had progressed to 
more severe stages.92 
 
On the opposite extreme, rapid progression has been defined as reaching H&Y stage 3 
within three years of disease onset, or reaching H&Y stage 4 or 5 within five years of 
disease onset.5  Marttila and Rinne reported 20 of 400 subjects with rapid progression.91  
Other studies, such as Goetz et al. have used similar definitions of rapid progression.93    
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  2.7.3 Prognostic Factors that predict progression of PD 
Progression of PD is heterogeneous across a population.4,91  It has also been shown that 
progression of PD is more rapid initially then slows down as the disease advances.94  Many 
studies have investigated different prognostic factors that predict progression of PD.  
Marras et al. conducted a systematic review of 13 articles investigating the predictors of 
motor decline and disability.95  Articles were chosen based on an assessment of 
methodological quality.  In this systematic review, most variables assessed in the different 
articles had inconclusive results for their ability to predict increased disability and motor 
impairment.  However, some variables demonstrated useful predictive value.  Five articles 
demonstrated a positive correlation between older age of onset and more rapid progression 
of disease.  In two separate articles by Hely et al. age of onset per 10 years was found to 
have a relatively consistent OR of about 3.0 when correlated with two different measures 
of progression of disease.34,96  PD is believed to be an active pathological process combined 
with an age-related neuronal degeneration.97  This neuronal degeneration increased with 
age97 and was reported to be eight to ten times higher in PD than in age matched 
controls.17,98  Others have suggested that old onset PD (OPD) has a different natural 
course with a different extent or rate of degeneration, that OPD manifests reduced 
compensatory mechanisms, and that the higher motor impairment is the result of co-
morbidities.36   
 
Five articles in the Marras et al. systematic review demonstrated that the predominance of 
tremor (TD) was correlated with a more benign progression of disease, while 
predominance of bradykinesia and rigidity were correlated with more rapid progression of 
PD.95  One study, in this systematic review, reported an OR of 0.43 for progression to 
H&Y stage 3 for patients with tremor dominant symptoms at baseline.  Marttila and Rinne 
also supported a more favorable prognosis for those patients who present at initial visit 
with TD compared to those with akinetic/rigid PD.91  Marras et al. also found one study 
that reported a predictive role for the Schwab and England activities of daily living scale.95  
A baseline ADL score below 70% was predictive of increased motor impairment and thus 
progression of disease.  Marras et al. found two studies that reported an association 
between the presence of dementia at baseline with more rapid motor decline and higher 
impairment.95   
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Some studies have reported differences in the duration of disease at baseline between 
subjects who have benign and rapid progression.  In one study the mean duration of 
disease was reported to be three times (8 years) longer in benign progression.99  Another 
study reported that patients with shorter disease duration progressed more rapidly.100   
 
Inconclusive results were reported by Marras et al. when investigating the predictive value 
of sex and depression.95  This paper also reported that several studies demonstrated no 
predictive value for rural living, family history of PD, smoking history, and presence of 
dyskinesias at baseline.   
 
Based on the findings of the Marras et al. systematic review, the prognostic characteristics 
associated with benign and rapid progression can be identified.95  Rapid progression was 
generally associated with older age at disease onset, predominance of bradykinesia and gait 
disturbances, ADL scores below 70%, and more frequent diagnosis of dementia.  Benign 
progression was characterized by younger age of disease onset, lateralization of 
Parkinsonian symptoms, predominance of tremor, and generally better prognosis and QoL.  
 
Although Marttila and Rinne completed a direct comparison of rapid and benign 
progression,91 more recent studies have tended to focus on comparisons of either rapid or 
benign progression against a control group.34,93,101  Another shortcoming of a majority of 
these studies is that they have short timeframes such as a two-year follow-up in the Goetz 
study,93 or a retrospective analysis of progression over one year as in the Hoehn and Yahr 
study.4  The shorter timeframes of these studies were a direct result of the study design.  
Subjects included in the studies were not receiving levodopa treatment.4,93  The endpoint of 
progression was often defined by the need for levodopa treatment due to progression to 
H&Y stage three.93,102  This limits the applicability of the results to a minority of PD 
subjects because the vast majority are eventually treated with levodopa.102  
 
A more recent study by Goetz et al. investigated some aspects of disease progression in 
levodopa-treated PD patients.102  They reported that progression of motor impairment was 
greater over a four year period for subjects who were in H&Y stage 3 at baseline compared 
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to subjects in H&Y stage 2 at baseline.  Although Goetz et al. are critical of previous 
studies conducted over a short timeframe, their study was conducted over a relatively short 
period of four years.102  Some studies, such as Hely et al. have been conducted over an 
extended period, but have limited their investigation of progression.34,92   
 
 2.8 Chapter Summary  
The prevalence and incidence of PD in Saskatchewan is the highest in all of Canada and 
over time has been increasing.  As such PD is a significant and growing health concern.  In 
general, studies demonstrated that some prognostic factors had significant associations 
with progression of PD.  Rapid progression was reported to be associated with older age of 
onset, the predominance of bradykinesia and rigidity, ADL scores below 70%, and the 
presence of dementia.  On the other hand, benign progression was reported to be 
associated with younger age of onset and the predominance of tremor.  Many other factors 
that were investigated, such as a family history of PD and smoking habit, had inconclusive 
results.   
 
Previous investigations generally had three limitations.  First, they had low numbers of 
subjects, second, progression was studied over a limited timeframe, and third, the study 
focused on either rapid or benign progression.  This thesis investigated the clinical features 
associated with benign and rapid progression using a single database and involved data 
collected over an extended period of time.  Another advantage is that this database 
included both levodopa treated and non-levodopa treated subjects at baseline.  
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CHAPTER 3 
Methodology 
 3.1 Study Locat ion  
This study was conducted at the University of Saskatchewan, Saskatoon, Saskatchewan 
in the College of Medicine, in (1) the Department of Community Health and 
Epidemiology; and (2) the Division of Neurology of the Department of Medicine. 
 
 3.2 Col le c t ed Data 
  3.2.1 The Clinical Dataset 
The dataset used in this study was a sub-set of a larger clinical database of Parkinsonian 
patients treated at one Movement Disorders Clinic in Saskatoon, Saskatchewan between 
1970 and February, 2005.  The vast majority of these patients were treated by one 
neurologist who was joined by another neurologist five years ago.  The clinical database 
contained 1648 subjects diagnosed with one form of Parkinsonism or another.  The dataset 
used for this study was restricted to patients clinically diagnosed with PD, which reduced 
the number of subjects to 1479.  Another 27 subjects were removed from the dataset 
because they did not have H&Y score,  or did not have a recorded date of onset of 
symptoms.  Thus, the dataset analyzed in this study contained 1452 subjects.  The dataset 
was de-identified so that individual identifying numbers such as Saskatchewan Health 
Services numbers and names had been removed. 
 
The scope, or catchment of this dataset includes patients who had been referred to the 
Movement Disorders Clinic by their family physician, or by another Neurologist.  Some of 
these patients may have been treated by their family physician for a number of years before 
referral because their condition had worsened and the family physician was seeking the 
assistance of a movement disorders specialist.  Other patients may have been referred to 
the clinic after an initial visit to their family physician had indicated a need for treatment by 
a movement disorders specialist.  Regardless of the specific reason for referral, the dataset 
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was comprised of patients who were at a more advanced stage of disease.  The frequency 
of follow-up varies in that some patients may have been seen only once because they were 
subsequently well managed by their family physician while other patients may have been 
seen infrequently, and yet other patients were seen as often as once ever three to nine 
months over many years. 
 
It is difficult to determine how representative this dataset was compared to the general 
population.   It is likely that a significant proportion of patients with PD in the Saskatoon 
Health Region have been seen in this movement disorders clinic, however the exact 
proportion is unknown.  A small number of patients have come to this clinic from other 
health regions in Saskatchewan.   
  
Patients had been asked a series of questions during initial and follow-up visits to the clinic 
with the intention of collecting clinically useful information that would assist the 
Neurologists in providing effective long-term medical intervention.  The other use of this 
database was to help the Neurologists identify potential participants in future clinical trials 
and studies as they became available.   
 
  3.2.2 Variable Selection 
The variables that were available for analysis are summarized in Table 3.1.  Some of these 
variables were not included in the study analysis for a number of reasons.  The variables of 
sleeping sickness, poisoning of any kind, tranquilizer use, drug abuse, and drug allergies 
were not included because they lacked analytic value for the study of disease progression.  
The dose of medication variables were not included in this study because much of this data 
was not entered into the electronic database.  Experimental drug and drug discontinued 
variables were not included in this analysis as these variables were collected for a specific 
drug trial conducted over a short period of time.  The variables reporting the site of 
disability were not included in the analysis because each respective disability site is highly 
correlated with the actual disability.  For example, there was no need to include the site of 
resting tremor variable when the variable of resting tremor was already in the analysis.   
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Table 3.1  Independent variables available in the database 
 
Variable  Categ ory Variable  Des cr ipt i on 
Personal Information Age of Onset  Age of patient’s recollection of first symptom 
 Sex Male or female 
 Place of Birth Urban, rural, unknown 
   
Relevant Past History Smoking History Current & past smoking habits 
 Stroke Ever had stroke 
 Seizures Ever had seizures 
 Family History of PD Any family member had PD 
 Sleeping Sickness Problems with getting to sleep and adequate sleep 
 Poisoning of any kind Any poisoning of any kind 
 Tranquilizer Use Any prolonged use of Tranquilizers 
 Drug Abuse Any use if illegal drugs 
 Drug Allergy Any allergies to drugs 
   
Use of Anti-Parkinson 
Medication 
Levodopa At first visit is patient taking this Medication 
 COMT Inhibitor At first visit is patient taking this Medication 
 Amantadine At first visit is patient taking this Medication 
 Anticholinergics At first visit is patient taking this Medication 
 Dopamine Agonist At first visit is patient taking this Medication 
 MAO-B Inhibitor At first visit is patient taking this Medication 
 Experimental Drugs Is patient enrolled in drug study 
 Dose of Medication Daily dose of any & all medications used 
   
Motor Fluctuations Response to Medications Any response to previous medications used 
 Adverse Effects Adverse effects to drug use 
 Dyskinesias Dyskinesias from drug use 
 Wearing Off Any wearing off 
 On-Off Any on-off periods  
 Drug Discontinued Ever ceased medication use 
   
Motor Function  
Assessment 
Tremor at Rest Any Tremor & Severity 
 TAR – Site Most Pronounced site of  TAR 
 Action Tremor Any Action tremor & severity 
 AT - Site Most Pronounced Site of AT 
 Postural Tremor Any postural tremor & severity 
 Rigidity Any rigidity & severity 
 Rigidity – Site Most Pronounced Site of rigidity 
 Bradykinesia Bradykinesia & severity 
 Bradykinesia – Site Most Pronounced Site of Bradykinesia 
   
Other Neurological 
Findings 
Schwab & England Activities of daily living assessment  
 Essential Tremor Is essential tremor present 
 Dementia Any dementia 
 Depression Any depression 
 Abnormal Eye Movement Any Abnormal Eye Movement 
 Cerebellar Dysfunction Any Known Cerebellar Dysfunction 
 Corticospinal 
Dysfunction 
Any Known Corticospinal Dysfunction 
 Sensory Abnormalities Any Sensory Abnormalities 
 Autonomic Dysfunction Any Autonomic Dysfunction 
 Peripheral Neuropathy Any Peripheral Neuropathy 
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The independent variables used in this analysis are summarized in Table 3.2.   Data was 
collected during the initial visit of each patient to the clinic.  All personal information 
variables were self-reported by the patient during the initial visit.  Place of birth was self-
reported as urban, rural, or unknown.  Date of onset was the year in which the first 
symptom of PD occurred as recollected by the patient in consultation with the neurologist.  
Disease duration was calculated by subtracting date of first visit from date of onset and was 
reported in years.  All relevant past history variables were also self-reported.  Most of the 
variables in this category were reported as yes, no, or unknown with the exception of 
smoking which was reported as current smoker, past smoker, never smoker, or unknown.  
All variables in the history of anti-Parkinson medication category were reported based on 
combined information from self-report of the patient during the initial visit and 
information provided to the neurologist in any consultation documentation that may have 
been provided.  The majority of these variables were recorded as either yes or no.  All 
variables in the motor fluctuation category were based on assessment by the neurologist 
and were recorded as yes or no.   
 
Most variables in the motor function assessment category were determined from the 
neurological examination performed at the initial visit.  These variables were recorded as an 
ordinal scale that indicated the severity of functional loss with the exception of ADL score.  
The ADL score is determined from patient responses to a series of questions concerning 
the patient’s perception of their current level of ability to perform tasks of daily living.  
This variable is reported as an interval scale from 0 to 100%.  This variable was 
dichotomized to scores above 70% and scores equal to or less than 70 percent. An ADL 
score ≤70% is clinically significant because the subject is not completely independent.  
Dementia and depression were self-reported as yes, no, or unknown. 
 
  3.2.3 Ethical Approval 
A study proposal was submitted to and approved by the Research Ethics Board 
(Biomedical) at the University of Saskatchewan (March 15, 2005 - Appendix A).   
 
Since this is a retrospective statistical and epidemiological analysis of a de-identified 
database the following assurances were made to the Research Ethics Board: 
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Table 3.2  Independent variables Used in Data Analysis  
 
Variab le  Ca teg or y Variab le  Descrip ti on Type 
Personal Information Age of Onset  Age of patient’s recollection of first symptom Interval & 
Nominal 
 Sex Male or female Nominal 
 Place of Birth Urban, rural, unknown Nominal 
 Disease Duration Disease Duration at First Visit Interval 
    
Relevant Past History Smoking History Current & past smoking habits Nominal 
 Stroke Ever had stroke Nominal 
 Seizures Ever had seizures Nominal 
 Family History of PD Any family member had PD Nominal 
    
Use of Anti-Parkinson 
Medication 
Levodopa At first visit is patient taking this Medication Nominal 
 COMT Inhibitor At first visit is patient taking this Medication Nominal 
 Amantadine At first visit is patient taking this Medication Nominal 
 Anticholinergics At first visit is patient taking this Medication Nominal 
 Dopamine Agonist At first visit is patient taking this Medication Nominal 
 MAO-B Inhibitor At first visit is patient taking this Medication Nominal 
    
Motor Fluctuations Response to 
Medications 
Any response to previous medications used Nominal 
 Adverse Effects Adverse effects to drug use Nominal 
 Dyskinesias Dyskinesias from drug use Nominal 
 Wearing Off Any wearing off occur Nominal 
 On-Off Any on-off periods  Nominal 
    
Motor Function  
Assessment 
Tremor at Rest Any Tremor & Severity Ordinal 
 Action Tremor Any Action tremor & severity Ordinal 
 Postural Tremor Any postural tremor & severity Ordinal 
 Rigidity Any rigidity & severity Ordinal 
 Bradykinesia Bradykinesia & severity Ordinal 
    
Other Neurological 
Findings 
Schwab & England Activities of daily living assessment  Nominal 
 Essential Tremor Is essential tremor present Nominal 
 Dementia Any dementia Nominal 
 Depression Any depression Nominal 
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    1.  Any use of the data, e.g., publication will be unlinked. 
    2.  No research subject will be contacted in any way to obtain additional information. 
    3.  The research results will be presented in aggregate fashion. 
 
 3.3 Methods o f  Analys is  
  3.3.1 Data Entry 
The data was initially entered in Microsoft “Excel” during the course of its clinical 
collection.  The data were then transferred to Microsoft “Access” before later transfer to 
Statistical Package for Social Sciences (SPSS ver. 13.0) software at the College of Medicine, 
Division of Neurology of the Department of Medicine.  Data checks were run for out-of-
range values and all edits were completed by May 3, 2005.  
 
  3.3.2 Data Analysis 
This was a retrospective cases-only study of a sample of 1452 PD patients.  Analysis was 
completed using SPSS ver. 13.0.  The first phase of this analysis was a descriptive analysis 
of the sample population at first clinic visit.  Frequency tables were produced for the 
selected independent variables listed in Table 3.2 along with the distribution of the H&Y 
scale in the sample population.  
 
In the second phase of this analysis subjects were divided into different progression 
groups.  Progression was defined in terms of how rapidly subjects progressed through the 
H&Y stages.  Diagnosis of H&Y stage was determined at initial and all subsequent clinic 
visits.  As such longitudinal use of the dataset was required in order to determine the 
progression category of each subject.  This study used existing definitions of “rapid” and 
“benign” progression.  Marttila and Rinne defined rapid progression as reaching H&Y 
stage 3 within three years of disease onset, or reaching H&Y stage 4 or 5 within five years 
of disease onset.5  Benign progression was characterized as still less than H&Y stage 3 ten 
years after disease onset.34,91  Average progression was defined as those who reached H&Y 
stage 3 between 4 and 10 years after disease onset, or in other words not benign nor rapid.  
Some subjects could not be allocated to the rapid, benign, or average groups due to 
insufficient follow-up information.  For example, a subject who attended the clinic for an 
initial visit may not have subsequent visit information because their disease was well 
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managed by their family physician.  As such, there is no follow-up information to 
categorize progression of this subject. This group of subjects was termed “unknown”.  A 
portion of the unknown group were termed “Unknown, but not rapid” and represents 
subjects who did not meet the criteria for rapid, but lacked information to be definitively 
categorized as either benign or average. For example, a subject who had an initial visit in 
1998 and was diagnosed in H&Y Stage 2 in a 2004 visit and has not had a subsequent visit 
since, does not have rapid progression, because they are not H&Y Stage 3 after three years 
nor H&Y Stage 4 or 5 after 5 years.  This subject lacks follow-up information to be 
categorized as benign progression because there is not 10 years of follow-up and the 
subject is not average because they have not reached H&Y Stage 3 as of yet.      
 
The third phase of the analysis was a series of univariable logistic regressions each 
containing a single independent variable.  This was conducted to identify factors associated 
with rapid and benign progression based on initial clinical findings.  For rapid progression 
the outcome variable was dichotomized into rapid progression, based on the definition 
established in phase two above, and “not rapid” progression, a combination of those 
allocated to the average, benign, and unknown, but not rapid groups.  For benign 
progression the outcome variable was dichotomized into benign progression, based on the 
definition established in phase two above, and “not benign” progression, those allocated to 
the average and rapid groups.  Univariable logistic regression was performed on each 
independent variable against the dichotomized outcome variables for both rapid and 
benign progression to obtain Odds Ratios (OR), 95% Confidence Intervals (CI), and p-
values for each independent variable.   
 
In the fourth phase of this analysis independent variables that were identified as statistically 
significant in the univariable analysis along with other independent variables deemed to be 
clinically and biologically important were selected for logistic regression modeling.  The 
specific logistic regression analysis used in this study was the stepwise backward 
elimination approach designed by Hosmer and Lemeshow.103   
 
It is important to understand that longitudinal information was used to categorize subjects 
into progression groups.  Those groups were then combined to generate dichotomous 
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outcome variables for logistic regression of benign and rapid progression.  These outcome 
variables were assessed for associations with independent variables at first clinic visit.  In 
other words, looking back at first clinic visit, what characteristics are associated with future 
progression of disease.   
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CHAPTER 4 
Results 
 4.1 Clin i cal  Charac t eri s t i c s o f  Sample  Populat ion  
There were 1452 patients in this sample population.  The clinical characteristics at first visit 
to the clinic are provided in Tables 4.1 to 4.4.  Table 4.1 summarizes demographic and 
clinical characteristics at first visit.  The mean age of onset was 65±11 years and ranged 
from 25 to 98 years.  The graph of age of onset (Figure 4.1) demonstrates a gradual 
increase in the number of patients with advancing age of onset which peaks at about 75 
years of age before falling off sharply.  The graph of disease duration (Figure 4.2) shows a 
sharp rise in the frequency of duration peaking at two years, and falling off gradually, and 
showing minimal frequencies after 10 years of disease duration. The mean disease duration 
was 4.4 years with a SD of 4.8 years and ranged from zero to 45 years.  Approximately 59% 
of the study population was male.  Over 63% were born in a rural setting.  About 12% of 
subjects reported being born in an urban setting while 24% did not report a place of birth.  
While approximately 37% had never smoked during their lives, over 51% had some past or 
current history of smoking.  The vast majority had no history of stroke or seizures.  About 
22% of subjects reported a family history of PD.   
 
Table 4.2 summarizes the use of anti-Parkinson medications and reported motor 
fluctuations at first visit.  About half the subjects were taking levodopa at their initial visit.  
Only about one percent of subjects were taking COMT Inhibitors.  About 10 to 15% of 
the study population was taking amantadine, anticholinergics, dopamine agonists, or MAO-
B inhibitors.  Although 25-35% of subjects experienced previous responses to medication 
use and adverse effects, 45-55% reported these effects as unknown.  Of those taking any 
medication, a small proportion were experiencing dyskinesias, wearing off, and on-off 
periods as a result. 
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Table 4.1  Demographic and Clinical Characteristics at First Visit  
 
Variable Frequency (%) 
  
N 1452 (100) 
  
Age of onset (years)  
     Mean (SD) 65.2 (11.0) 
     Range 25 to 98 
  
Disease Duration  
     Mean (SD) 4.4 (4.8) 
     Range 0 to 45 
  
Sex  
     Male 859 (59.2) 
     Female 593 (40.8) 
  
Place of Birth  
     Urban 170 (11.7) 
     Rural 922 (63.5) 
     Unknown 360 (24.8) 
  
Smoking History  
     Never 543 (37.4) 
     Past 632 (43.5) 
     Current 114 (7.9) 
     Unknown 163 (11.2) 
  
Stroke  
     Yes 71     (4.9) 
     No 1189 (81.9) 
     Unknown 192   (13.2) 
  
Seizures  
     Yes 18     (1.2) 
     No 1244 (85.7) 
     Unknown 190   (13.1) 
  
Family History PD  
     Yes 316   (21.8) 
     No 1053 (72.5) 
     Unknown 83     (5.7) 
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Figure 4.1  Age of Onset at First Visit of Study Population (N=1452) 
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Figure 4.2  Disease Duration at First Visit of Study Population (N=1452) 
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Table 4.2  Use of Anti-Parkinson Medications and Reported Motor Fluctuations  
at First Visit  
 
Variable Frequency (%) Variable Frequency (%) 
Levodopa  Previous Medication Response  
     Yes 728  (50.1)      Yes 516  (35.5) 
     No 721  (49.7)      No 125  (8.6) 
     Unknown 3      (0.2)      Unknown 811  (55.9) 
    
COMT Inhibitor  Previous Adverse Effects  
     Yes 18     (1.2)      Yes 320  (22.0) 
     No 1432 (98.6)      No 478  (32.9) 
     Unknown 2       (0.1)      Unknown 654  (45.0) 
    
Amantidine  Previous Dyskinesias  
     Yes 188   (12.9)      Yes 111  (7.6) 
     No 1261 (86.8)      No 575  (39.6) 
     Unknown 3        (0.2)      Unknown 766  (52.8) 
    
Anticholinergics  Previous Wearing off  
     Yes 153   (10.5)      Yes 59   (4.1) 
     No 1297 (89.3)      No 575 (39.6) 
     Unknown 2       (0.1)      Unknown 818 (56.3) 
    
Dopamine Agonists  Previous On-Off Periods  
     Yes 163   (11.2)      Yes 10   (0.7) 
     No 1286 (88.6)      No 605 (41.7) 
     Unknown 3       (0.2)      Unknown 837 (57.6) 
    
MAO-B Inhibitor    
     Yes 228   (15.7)   
     No 1220 (84.0)   
     Unknown 4       (0.3)    
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Table 4.3 summarizes the motor function assessment findings at first visit.  Approximately 
80% of subjects presented with some form of resting tremor, of which the majority had 
slight to mild symptom severity.  Over 90% of subjects at first visit had symptoms of 
bradykinesia, noted on exam; in almost half it was of moderate severity.  Action tremor was 
present in about 70% of the study population, however most subjects experienced slight 
severity.  Rigidity was present in over 95% of subjects, most of which was slight to 
moderate in severity.  Approximately 20% of the study population had either the presence 
or absence of postural tremor noted on initial visit.  Nearly twice as many had presence 
compared to absence of postural tremor.   
 
Table 4.4 summarizes other neurological findings at first visit.  About 65% of the study 
population had a reported ADL score, of which approximately 30% had an ADL score 
below 70 percent.  The mean ADL score was 81.6±19.4%, the median score was 90%, and 
the range was 10 to 100 percent.  The vast majority of subjects did not have essential 
tremor or dementia at first visit.  Only about 20% of the study population had reported the 
presence or absence of depression, of which about 10% had reported depression at first 
visit.  The H&Y disability was distributed in this population as follows: about 70% mild 
disability, those in H&Y stages 1 and 2, and approximately 22% moderate disability, those 
in H&Y stage 3, and about 7% severe disability, those in H&Y stages 4 and 5.   
 
4.2 Dis t ribut ion by Progression  
Figure 4.3 illustrates the flow chart of inclusion criteria for this study and the distribution 
by progression.  The entire database is a collection of subjects who were treated at the 
Movement Disorders Clinic from 1970 to February 2005.  These subjects were all 
suspected cases of Parkinsonism.  For this study subjects who received a follow-up clinical 
diagnosis of IPD were included.  Subjects with other diagnoses such as PSP, drug induced 
Parkinsonism and so on were excluded as were subjects who did not have a reported year 
of onset of symptoms, or H&Y score.  As a result 196 subjects were excluded from this 
analysis leaving 1452 subjects in the sample population.   
 
As described earlier in Chapter 3, the sample population was divided into three different 
progression groups; rapid, benign, and average.  The distribution by progression is  
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Table 4.3   Motor Function Assessment at first visit  
 
Variable Frequency (%) 
  
Resting Tremor  
     Absent 284  (19.6) 
     Slight 421  (29.0) 
     Mild  613  (42.2) 
     Moderate 120  (8.3) 
     Marked 7      (0.5) 
     Unknown 7      (0.5) 
  
Bradykinesia  
     Normal 70   (4.8) 
     Mild 337 (23.2) 
     Moderate 665 (45.8) 
     Severe 346 (23.8) 
     Barely performs task 22   (1.5) 
     Unknown 12   (0.8) 
  
Action Tremor  
     Absent 478  (32.9) 
     Slight 703  (48.4) 
     Moderate 227  (15.6) 
     Moderate (+) 13    (0.9) 
     Marked 2      (0.1) 
     Unknown 29    (2.0) 
  
Rigidity  
     Absent 59   (4.1) 
     Slight 532 (36.6) 
     Mild to Moderate 713 (49.1) 
     Marked 136 (9.4) 
     Severe 4     (0.3) 
     Unknown 8     (0.6) 
  
Postural Tremor  
     Yes 199   (13.7) 
     No 106   (7.3) 
     Missing Information 1147 (79.0) 
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Table 4.4  Other Neurological Findings at first visit  
 
Variable  Frequency (%) 
  
Schwab & England ADL Score  
     ≤ 70% 224  (15.4) 
     > 70 % 717  (49.4) 
     Missing Information 511  (35.2) 
  
Essential Tremor   
     Yes 76     (5.2) 
     No 1361 (93.7) 
     Unknown 1       (0.1) 
     Missing Information 14     (1.0) 
  
Dementia  
     Yes 93     (6.4) 
     No 1293 (89.0) 
     Unknown 66     (4.5) 
  
Depression  
     Yes 25     (1.7) 
     No 265   (18.3) 
     Unknown 4       (0.3) 
     Missing Information 1158 (79.8) 
  
Hoehn & Yahr Scale   
     1 236  (16.3) 
     2 793  (54.6) 
     3 330  (22.7) 
     4 50    (3.4) 
     5 43    (3.0) 
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Figure 4.3 Flow Chart of Distribution by Progression Category 
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illustrated in Figure 4.3.  We were unable to classify 181 (12.4%) subjects due to 
insufficient follow-up information, or the first clinic visit was more than 10 years after 
onset of symptoms.  About 27% (387 subjects) of the sample population could only be 
classified as “not rapid” in that they did not meet the criteria for rapid progression, but did 
not have sufficient follow-up information to confirm benign or average progression.  The 
frequency of both benign and rapid progression was virtually the same at about 17 percent.  
Those subjects classified with average progression represented about 27% of the sample 
population.   
 
 4.3 Benign Progress ion  
  4.3.1 Univariable Analysis for Benign Progression 
Univariable analysis of the independent variables against benign progression was 
conducted.  Those variables that were determined to be statistically significant by 
univariable analysis along with those variables determined to be biologically and/or 
clinically important are presented in Table 4.5.  In accordance with the protocol established 
by Hosmer and Lemeshow those variables that had reported p-values of 0.25 or less were 
retained for later multivariable analysis.103   
 
For every 10 year increase in age of onset subjects were one third as likely to develop 
benign progression.  This result was significant with a reported p-value of <0.001.  The 
narrow CI indicates good precision of this estimate.  For every one year increase in disease 
duration subjects were 1.30 times more likely to have benign progression.  The result was 
significant with a reported p-value of <0.001.  The narrow CI indicates good precision of 
this estimate.  Men were 1.86 times more likely to develop benign progression as women.  
The result is highly significant with a p-value of <0.001 and the narrow CI indicates good 
precision of this estimate.   
 
Subjects who were current smokers at first visit were 2.36 times more likely to have benign 
progression.  The result was significant with a p-value of 0.004.  Subjects with a past 
history of smoking were slightly less likely to have benign progression.  The result was 
significant with a p-value of 0.034.  There was good precision in both of these estimates as 
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Table 4.5  Univariable Analysis of Significant Independent Variables for Benign 
Progression 
 
Variable N (%) Benign N (%) not Benign a Odds Ratio CI p-value 
      
N 248 636    
      
Age of Onset *** 56.1 (10.8) 68.8 (9.7) 0.32 0.27,  0.38 0.001 
      
Disease Duration **** 8.0 (7.0) 3.5 (2.5) 1.30 1.24,  1.36 <0.001 
      
Male 164 (66.1) 326 (51.3) 1.86 1.37,   2.52 <0.001 
      
Smoking History      
     Past 82 (37.8) 278 (49.6) 0.70 0.50,  0.97 0.034 
     Current 27 (12.4) 27 (4.8) 2.36 1.32,  4.21 0.004 
      
Stroke * 6 (2.9) 40 (7.4) 0.37 0.15,  0.88 0.025 
      
Family history PD * 67 (28.3) 120 (20.0) 1.58 1.12,  2.23 0.010 
      
Levodopa * 138 (55.6) 336 (53.0) 1.11 0.83,  1.50 0.478 
      
Other Medications * 125 (50.4) 227 (35.7) 1.83 1.36,  2.46 <0.001 
      
Motor Fluctuations * 138 (86.3) 294 (76.6) 1.92 1.16,  3.19 0.012 
      
Resting Tremor ** 133 (53.8) 303 (47.9) 0.77 0.58,  1.04 0.088 
      
Rigidity ** 42 (27.5) 404 (63.7) 1.46 1.08,  1.96 0.014 
      
Bradykinesia ** 154 (63.1) 484 (76.6) 1.91 1.39,  2.63 <0.001 
      
ADL ≤ 70% 14 (11.8) 149 (39.4) 0.21 0.11,  0.37 <0.001 
      
Dementia * 9 (3.7) 49 (8.1) 0.44 0.21,  0.91 0.026 
      a      not benign group is combination of the average and rapid groups (refer to Figure 4.3) 
   *      Reported values are for a response of yes.   
   **    Reported values are for mild to severe severity of the symptom.   
   ***  Represents OR for a 10 year increase in age of onset.   
   **** Represents OR for a 1 year increase in disease duration.   
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indicated by the narrow CI’s.  Those subjects with a reported history of stroke were 
significantly less likely to have benign progression with an OR of 0.37.  The result was 
statistically significant with a p-value of 0.025 and the narrow CI indicates good precision 
of this estimate.  Subjects with a family history of PD were 1.58 times more likely to have 
benign progression.  The result was statistically significant with a p-value of 0.010.  There 
was good precision of this estimate as indicated in the narrow CI.  Subjects who were 
taking levodopa at first visit or had reported prior use of levodopa were slightly more likely 
to have benign progression.  The narrow CI indicates good precision of this estimate.  
 
All anti-Parkinson medications excepting levodopa were combined into a single variable 
called Other Medications.  This variable was binomial and yes to other anti-Parkinson 
medication use was defined as a yes to use of any one or more of the other anti-Parkinson 
medications.  The motor fluctuation variables were combined into a single variable called 
Motor Fluctuations.  This variable was binomial and a yes to the presence of motor 
fluctuations was defined as a yes to presence of any one or more motor fluctuations.  The 
results of univariable analysis demonstrated that subjects who were taking or had a history 
of taking any other medications were 1.83 times more likely to have benign progression.  
The result was highly significant with a p-value of <0.001.  Subjects with motor 
fluctuations were 1.92 times more likely to have benign progression.  The result was highly 
significant with a p-value of 0.012.  Both estimates had good precision as indicated by the 
narrow CI’s.   
 
Each motor function assessment variable, excepting postural tremor, has five levels of 
severity rated on an ordinal scale from zero to four.  The results show that several of these 
severity levels had very low or absent reported values.  As such, the levels of severity for 
these variables were dichotomized by grouping absent and slight severity, a score of 0 or 1, 
into one category and grouping mild to severe severity, a score of 2,3, or 4, into another 
category.  Univariable analysis (Table 4.5) showed that subjects with mild to severe resting 
tremor were less likely to have benign progression with a reported OR of 0.77.  The result 
had borderline significance with a reported p-value of 0.088.  Subjects with mild to severe 
rigidity were 1.46 times more likely to have benign progression.  The result was highly 
significant with a p-value of 0.014.  Subjects with mild to severe bradykinesia were nearly 
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twice as likely to have benign progression.  The result was highly significant with a p-value 
<0.001.  All of the CI’s for these motor function assessments were narrow indicating good 
precision of the estimates.  
 
Subjects with self-reported ADL scores of 70% or less were unlikely to have benign 
progression.  The result was statistically significant with a p-value <0.001.  Subjects with a  
reported history of dementia were about half as likely to have benign progression.  The 
result was statistically significant with a p-value of 0.026.  Both of these variables had 
narrow CI’s indicating good precision of the estimates.  
 
  4.3.2 Multivariable Logistic Regression for Benign Progression 
From univariable logistic regression analysis it was determined that age of onset, disease 
duration, sex, smoking history, family history of PD, other medications, motor 
fluctuations, stroke, resting tremor, rigidity, bradykinesia, ADL, and dementia all had some 
association with benign progression and as such would be included in the multivariable 
logistic regression model based on significant p-values less than 0.25.  Levodopa was also 
included based on its clinical significance.  Multivariable logistic regression was conducted 
on these variables using backward stepwise elimination method using the Likelihood Ratio 
Test in SPSS ver. 13.0.   Interaction tests had no impact on the outcome of the final model.  
A second multivariable logistic regression analysis was performed with the ADL variable 
removed from the model.  ADL was removed because over 35% of the reported values 
were missing.  The final multivariable model is presented in Table 4.6.   
 
Age of Onset, disease duration, sex, smoking history, levodopa, and rigidity remained 
significant after multivariable analysis.  In the multivariable model for every 10 year 
increase in age of onset at first visit subjects were one third as likely to have benign 
progression.   For every one year increase in disease duration at first visit subjects were 1.41 
times more likely to have benign progression.  Males were 3.23 times more likely to have 
benign progression.  Subjects who reported a past history of smoking were less than half as 
likely to have benign progression as non-smokers, while current smokers were 2.33 times 
more likely to have benign progression as non-smokers.  Subjects who reported past or 
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Table 4.6 Final Model from Multivariable Analysis for Benign Progression (N=400)  
 
Vari ab le s Odds Rat io C.I . p-va lue 
Age of Onset * 0.36 0.25,  0.50 0.000 
Disease Duration ** 1.41 1.27,  1.57 0.000 
Male 3.23 1.70,  6.16 0.000 
Smoking Habit    
     Past Smoker  a 0.46 0.24,  0.89 0.021 
     Current Smoker  a 2.33 0.67,  8.11 0.184 
Levodopa *** 0.45 0.21,  0.98 0.043 
Rigidity **** 0.43 0.23,  0.80 0.008 
   * Represents OR for a 10 year increase in ago of onset 
   ** Represents OR for an increase of 1 year in disease duration  
   *** Reported values are for a response of yes 
   ****  Reported values are for mild to severe severity of symptom 
     a  Reference category is Never Smoking  
 
 
current use of levodopa were about half as likely to have benign progression.  Subjects who 
had mild to severe rigidity were about half as likely to have benign progression as those 
subjects with absent or slight rigidity.   
 
Age of Onset, disease duration and male sex had stronger associations while smoking 
history, levodopa use, and rigidity had weaker associations when controlling for other 
variables.  Male sex was the only variable with a stronger association to demonstrate a 
meaningful difference between the crude and adjusted OR’s where it increased by over 73 
percent.   Past history of smoking, levodopa use, and rigidity all demonstrated meaningful 
decreases from crude to adjusted OR’s by 34%, 59% and 69% respectively.  Both levodopa 
use and rigidity had their associations with benign progression flip from positive to 
negative.   
 
4.4 Rapid Prog ress ion  
  4.4.1 Univariable Analysis for Rapid Progression 
Univariable analysis of the independent variables against the rapid progression outcome 
was conducted.  Variables determined to be statistically significant by univariable analysis 
along with variables determined to be biologically and/or clinically important are presented 
in Table 4.7.  In accordance with the protocol established by Hosmer and Lemeshow those 
variables that had reported p-values of 0.25 or less were retained for later multivariable 
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analysis.103  For every 10 year increase in age of onset subjects were over three times as 
likely to have rapid progression.  This result was significant with a reported p-value of 
<0.001.  The narrow CI indicates good precision of this estimate.  For every one year 
increase in disease duration subjects were 0.63 times less likely to have rapid progression.  
The result was highly significant with a p-value of <0.001.  The very narrow CI indicates 
good precision for this estimate.   
 
Males were less likely to have rapid progression than women, an effect that was statistically 
significant.  The precision of the estimate was good as reflected in the narrow CI.  Subjects 
with a history of past and current smoking habits were less likely to have rapid progression.  
Since the CI’s are narrow the precision of this estimate is good.  Subjects with a self-
reported family history of PD were half as likely to have rapid progression.  This effect was 
statistically significant with a p-value of 0.001.  The narrow CI indicates good precision of 
the estimate.  Subjects taking levodopa were slightly less likely to have rapid progression.  
There is good precision in this estimate as reflected in the narrow CI.  
 
All anti-Parkinson medications excepting levodopa were combined into a single variable 
called Other Medications.  This variable was binomial and yes to other anti-Parkinson 
medication use was defined as a yes to use of any one or more of the other anti-Parkinson 
medications.  The motor fluctuation variables were combined into a single variable called 
Motor Fluctuations.  This variable was binomial and a yes to the presence of motor 
fluctuations was defined as a yes to presence of any one or more motor fluctuations.  The 
results of univariable analysis demonstrated that those subjects who were taking or had a 
history of taking any other medications were half as likely to have rapid progression.  The 
result was highly significant with a p-value of <0.001.  Subjects with motor fluctuations 
were about half as likely to have rapid progression.  The result was slightly above 
significance level with a p-value of 0.056.  Both estimates have good precision as indicated 
in the narrow CI’s.   
 
Each disability assessment variable, excepting postural tremor, has five levels of severity 
reported on an ordinal scale from zero to four.  The results show that several of these 
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Table 4.7 Univariable Analysis of Significant Independent Variables for Rapid 
Progression 
 
Variable N (%) Rapid N (%) not Rapid 
a 
Odds Ratio CI p-value 
N 246 1025    
      
Age of Onset *** 72.8 (9.0) 63.3 (10.7) 3.09 2.54,  3.75 <0.001 
      
Disease Duration **** 2.0 (1.1) 4.8 (4.5) 0.63 0.57,  0.69 <0.001 
      
Male 125 (50.8) 622 (60.7) 0.67 0.51,   0.89 <0.001 
      
Smoking History      
     Past 104 (47.7) 443 (48.6) 0.91 0.67,  1.23 0.540 
     Current 14 (6.4) 82 (9.0) 0.66 0.36,  1.21 0.182 
      
Family history PD * 35 (14.9) 246 (25.5) 0.51 0.35,  0.75 0.001 
      
Levodopa * 113 (46.1) 524 (51.2) 0.82 0.62,  1.08 0.156 
      
Other Medications * 66 (26.8) 426 (41.6) 0.52 0.38,  0.71 <0.001 
      
Motor Fluctuations * 101 (73.2) 501 (80.5) 0.66 0.43,  1.01 0.056 
      
Resting Tremor ** 98 (39.8) 558 (54.8) 0.55 0.41,  0.73 <0.001 
      
Rigidity ** 166 (67.5) 591 (58.1) 1.50 1.12,  2.01 0.007 
      
Bradykinesia ** 196 (79.7) 716 (70.5) 1.64 1.17,  2.30 0.004 
      
Postural Tremor * 35 (76.1) 114 (63.0) 1.87 0.89,  3.93 0.098 
      
ADL ≤ 70% 73 (46.5) 110 (17.3) 4.16 2.86,  6.05 <0.001 
      
Dementia * 24 (10.1) 52 (5.4) 2.00 1.21,  3.32 0.007 
a      not rapid is combination of Average, benign, and unknown, but not rapid groups (refer to 
       Figure 4.3) 
*      Reported values are for a response of yes.   
**    Reported values are for mild to severe severity of the symptom.   
***   Represents OR for a 10 year increase in age of onset.   
**** Represents OR for a 1 year  increase in disease duration.   
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severity levels have very low or absent reported values.  As such the levels of severity  
for these variables were dichotomized by grouping absent and slight severity, a score of 0 
or 1,  into one category and grouping mild to severe severity, a score of 2, 3, or 4,  into 
another category.  Univariable analysis (Table 4.7) showed that those subjects with mild to 
severe resting tremor were half as likely to have rapid progression with a reported OR of 
0.55.  Subjects with mild to severe rigidity were 1.50 times more likely to have rapid 
progression.  The result was highly significant with a p-value of 0.007.  Subjects with mild 
to severe bradykinesia were 1.64 times more likely to have rapid progression.  The result 
was highly significant with a p-value of 0.004.  All of the CI’s for these disability 
assessments were narrow indicating good precision of the estimates.  
 
Subjects with postural tremor were 1.87 times more likely to have rapid progression.  
Subjects with ADL scores ≤ 70% were 4.16 times more likely to have rapid progression.  
The result was highly significant and the narrow CI indicates good precision of the 
estimate.  Subjects who reported having dementia at first visit were twice as likely to have 
rapid progression.  The result was highly significant and had good precision indicated by 
the narrow CI.  
 
  4.4.2 Multivariable Logistic Regression for Rapid Progression   
From the univariable logistic regression analysis it was determined that the variables of age 
of onset, disease duration, sex, smoking history, family history of PD, levodopa, other 
medications, motor fluctuations, resting tremor, rigidity, bradykinesia, and dementia all had 
some association with rapid progression and as such would be included in the multivariable 
logistic regression model based on significant p-values less than 0.25.  Although ADL and 
postural tremor had statistically significant associations with rapid progression in 
univariable analysis, they were not included in multivariable analysis because 35% and 79% 
of reported values (respectively) were missing.  Multivariable logistic regression was 
conducted using backward elimination stepwise method in SPSS.  Interaction tests had no 
impact on the outcome of the final model.  The final multivariable model is presented in 
Table 4.8. 
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Age of onset, disease duration, male sex, resting tremor, and rigidity remained significant 
after multivariable analysis.  In the multivariable model, for every 10 year increase in age of 
onset at first visit, subjects were 2.45 times more likely to have rapid progression.   For 
every one year increase in disease duration at first visit subjects were half as likely to have 
rapid progression.  Male subjects were about half as likely to have rapid progression.  
Subjects with mild to severe resting tremor were about half as likely to have rapid 
progression as subjects with absent or slight severity.  Subjects with mild to severe rigidity 
were nearly twice as likely to have rapid progression as subjects with absent or slight 
severity.   
 
 
Table 4.8  Final Model from Multivariable Analysis for Rapid Progression (N=617) 
 
Vari ab le s Odds Rat io C.I . p-va lue 
Age of Onset * 2.45 1.80,  3.33 <0.001 
Disease Duration ** 0.52 0.44,  0.62 <0.001 
Male 0.58 0.35,  0.95    0.03 
Resting Tremor *** 0.47 0.28,  0.77    0.003 
Rigidity *** 1.73 1.02,  2.94    0.044 
* Represents OR for a 10 year increase in age of onset 
** Represents OR for a 1 year increase in disease duration 
*** Reported OR is for mild to severe severity of symptom 
 
 
Rigidity had a stronger association, while age of onset, disease duration, male sex, and 
resting tremor had weaker associations when controlling for other variables.  Although 
rigidity had a 15.3% higher adjusted OR compared to crude OR in univariable analysis, the 
difference was not meaningful.  Of those variables with weaker associations only age of 
onset had a meaningful difference between the crude and adjusted OR with a 20.7% 
decrease.  Disease duration, male sex, and resting tremor had weaker associations with 
17.5%, 13.4%, and 14.5% decreases from crude to adjusted OR’s respectively.   
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CHAPTER 5 
Discussion 
 5.1 Charac t eri s t ic s  o f  Sample  Populat ion  
Compared to previous disease progression studies our study population had some 
similarities and some differences.  The size of this sample population was more than 
double the Hoehn and Yahr study 4 and was up to five times larger than a majority of 
previous studies of disease progression.94,98,100,101,104  Other retrospective studies have 
utilized data from specialist’s clinics 94 and epidemiological surveys.91  Previous studies 
investigating disease progression have also used specialist clinical data,4,98,101 or 
administrative data,97,105 or have been community based studies.100  The mean age of onset 
of the current study population was 8 to 10 years older than previous studies that used 
specialist clinical data.4,94,98  Other investigations using a community based cohort,100 
outpatient clinical data,105 or an epidemiological survey 91 reported an age of onset similar to 
our study population.  These findings support the assertion that the current study 
population is a representative community sample.  
 
Disease duration at first visit was shorter than previous retrospective studies by about 2 to 
3 years.91,94  Most of the previous studies were conducted in the US and all reported longer 
disease duration than this study.94,98,100  A Canadian study by Lee et al. reported disease 
duration double what this current study found.104  The observed longer disease duration at 
first visit in the Lee et al. study may reflect a selection bias because a portion of their study 
population was recruited from chronic care facilities.104   On the other hand, the shorter 
disease duration at first visit in our study could reflect earlier referral to specialist care.  
  
Most studies reported a predominance of males in their study populations of around 60%, 
similar to the current study.4,94,98,100  Although no studies of progression investigated the 
potential role for rural place of birth, two studies did investigate the potential role of rural 
living.93,106  In one of these studies those who had lived in a rural setting for 10 years or 
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more comprised 60% of the total study population, a figure similar to our study 
population.106  It is likely that both our study and the Ferraz et al. study would normally 
have a preponderance of rural subjects given that both the Canadian prairies and Brazil are 
predominantly agricultural.106 
 
Previous PD studies reported 5-18% of PD patients as current smokers.60, 101  The reported 
occurrence of current smokers in our study falls within that range.  Studies reported that 
15-24% of PD subjects had a pathological diagnosis of stroke.107, 108  One study reported a 
cumulative incidence of lifetime ischemic stroke in PD patients of 8 per 100.109  Our study 
reported about 5% incidence of stroke at first visit.  In general it has been reported that 
about 10-24% of PD subjects have some form of family history of PD.86  The results of 
our study fall within that range.   
 
Earlier studies of progression, such as Hoehn and Yahr 4 and Marttila and Rinne,91 were 
conducted on patients who were not taking anti-Parkinson medications.  Some of the more 
recent studies have investigated progression either with levodopa treatment,99, 102 or prior to 
levodopa treatment.110  The Roos et al. study, which did not manipulate pharmacological 
treatments, reported that 80% of subjects were taking levodopa at baseline.105  Another 
progression study reported that 70% of their subjects were taking levodopa at baseline.100  
These results demonstrate a much higher frequency of levodopa use at baseline than our 
study.  The lower preponderance of levodopa use in our study could result from earlier 
referral to the clinic.  On the other hand, the elevated use of levodopa observed in previous 
studies could reflect longer disease duration and a higher likelihood of medication use at 
first visit.100  The potential association of reported motor fluctuations at baseline with 
progression was not investigated in previous studies.   
 
Similar to previous studies motor function assessment revealed that the majority of patients 
present with mild or slight severity of the respective sign.94,105  The only previous study to 
investigate the potential association of ADL with progression reported mean and median 
baseline Schwab and England scores of 69.2% and 70.0% respectively, while the subjects in 
our study had mean and median scores of 81.6% and 90.0% respectively.100  The Schwab 
and England is a self-reported ordinal scale indicating the degree to which activities of daily 
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living are compromised.  A score below 70% is clinically significant because patients are 
not completely independent and spend a large part of their day completing chores.  Since 
subjects in the Louis et al. study had longer disease duration at baseline, it is probable that 
they had more compromised motor function as reflected in lower ADL scores.100  
 
The distribution of H&Y stages in our study population was comparable to previous 
studies.  The majority of subjects were diagnosed with H&Y Stage 1 or 2 at the 
commencement of various studies.4,91,96,105  Although our study found a similar frequency of 
subjects in H&Y Stage 2, there was about 1.5 to 2.5 times as many subjects in H&Y Stage 1 
than in previous studies.91,96  While a similar frequency of subjects was observed in H&Y 
Stage 3, there were fewer subjects in H&Y Stages 4 and 5 in our study than in previous 
studies.91,105  Subjects appear to be referred to this clinic earlier and as such may have less 
global disability at baseline.   
 
The occurrence of dementia at first visit in our study is much lower than previous studies 
with reported frequency at baseline of about 15 to 19 percent.105,111  The smaller sample size 
of these two studies could have contributed to the higher reported occurrence of dementia.  
However, neither study clearly indicated how dementia was assessed.  A systematic review 
of 26 studies of depression in PD reported a mean frequency of 40% and a range of 4-70 
percent.112  The authors did comment that the wide range in reported frequency could have 
resulted from different definitions of depression.  The study demonstrates an association 
between depression and PD.  The frequency of depression reported in our study falls 
below the above reported range.  This is probably because we were reporting the 
occurrence of depression at first visit while the majority of the studies in the systematic 
review reported lifetime frequency.   
 
In general, the characteristics of our study population are quite similar to those of previous 
studies as evidenced by similar male to female ratio, similar frequencies of current smoking, 
stroke, and family history, and similar baseline distribution of H&Y scores.  Unlike 
previous studies we reported higher ADL scores, shorter disease duration, and less 
frequent levodopa use at baseline.  All of these differences though can be attributed to 
earlier referral to this clinic.   
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 5.2 Observat ions  on Univariable  Analys i s  
In the analysis of benign progression the OR’s for levodopa use and rigidity flipped from  
positive associations in univariable analysis to negative associations in multivariable 
analysis.  Univariable analysis represents the association of a single variable with the 
measured outcome.  In this case levodopa use by itself and the presence of mild to severe 
rigidity by itself were apparently predictive of benign progression of disease.   However, 
univariable analysis can only provide information on the effect of a single variable.  It is 
only a single piece of a larger more complex picture of the true biological situation.  Rarely 
would levodopa use be the only available piece of information.  If it was, then univariable 
analysis would inform us of its impact on benign progression.  Statistically, univariable 
analysis is conducted to inform us of which available variables are potentially significant.  
Thus, rather than putting all available variables into a multivariable model, we can select 
potentially significant variables for inclusion.  Multivariable analysis accounts for the 
interactive effect of many variables that would naturally co-exist.  It is a larger, more 
complex picture of the true biological situation.  In this case, levodopa use and rigidity in 
the presence of each other and the other variables in the final model interact together in 
informing the prediction of benign progression. 
 
The univariable analyses of rigidity, bradykinesia, and resting tremor all had associations 
that were in the same direction in both the rapid and benign analysis.  Taken alone, these 
univariable results show that mild to severe rigidity and bradykinesia and absent or slight 
resting tremor were predictive of both benign and rapid progression.  This conclusion is 
counter-intuitive.  As discussed above, univariable analysis only provides information on a 
single variable.  The multivariable models of benign and rapid progression reveal the effect 
of many variables that combined predict both rapid and benign progression.  The 
differences between the two models is discussed in more detail below (Section 5.5).   
 
 5.3 Benign Progress ion  
Subjects with benign progression had longer disease duration at first visit and had younger 
age of onset of PD compared to the not benign group.  This result was consistent with 
previous studies.91,94,97,99  The observed age of onset in the benign group of this study was 
similar to that reported by Birkmayer et al.,99 but was 16 years older than that reported in 
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the Marttila and Rinne study.91  Since the Marttila and Rinne study restricted its benign 
group to those with unilateral symptoms their benign group did not include those in H&Y 
Stage 2.  This could account for the lower age of onset and would also account for the 
smaller reported size of their benign group, which was about one third the frequency of 
our benign group.  The observed disease duration in the benign group in this study was 
shorter than that reported in other studies.91,99  Birkmayer et al. reported a mean disease 
duration of 23 years, three times what we observed.99  The fact that the Birkmayer et al. 
benign group only included those with unilateral symptoms after 10 years could account 
for this difference.99  
 
This current study found that males were more likely to experience benign progression 
than females, was different than previous studies that reported no differences in 
progression for males and females.96,99,113  Our findings also appear to contradict the finding 
by Jankovic and Kapadia that males progress at a significantly higher rate than females.94  
However, the Jankovic and Kapadia study followed subjects for only three years and used a 
different definition of progression than we employed.  Other studies have suggested that 
PD progresses more rapidly initially and then slows down as the disease advances.85,104   In 
these studies progression was defined in terms of decline in Fluorodopa uptake, a surrogate 
for loss of dopamine cells in the substantia nigra.  Neither study reported a sex difference 
in progression of disease.  Since our study covers a much longer period of follow-up, we 
could be reporting a higher likelihood of long-term benign progression in males even 
though they may initially progress at a more rapid rate.   
 
Subjects with past history of smoking were less likely to have benign progression, while 
those who were current smokers at first visit were more likely to have benign progression.  
Other studies found no significant association between smoking and progression of 
disease.93,114  Both of these studies however involved a small sample population studied 
over a short timeframe.  The Alves et al. study 114 had a longer period of study than Goetz 
et al.,93 but was still less than half the time of our study.  Alves et al. reported no differences 
between smokers and non-smokers regarding changes to UPDRS scores, H&Y scale, and 
ADL scores over the course of the study.114   Since they defined smokers as those subjects 
who were smoking at the time of the initial evaluation, the non-smoking category 
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represents both past smokers and never smokers.  Grouping these two categories 
underestimates the effect of a history of smoking.  Goetz et al. did investigate a possible 
dose effect of smoking, but their study had only 31 matched pairs that were followed for 
only three years.93  
 
The current study found that patients who had taken or were taking levodopa at first visit 
were less likely to have benign progression.  Other studies that investigated a potential 
predictive role for levodopa use reported no significant association between levodopa use 
and progression of disease.100,105  It is possible that any potential association could have 
been masked by the fact that 70-80% of the sample populations in those two studies were 
taking levodopa at baseline.  Subjects in the Roos et al. study, who were taking levodopa, 
could be at more advanced disease stage as evidenced in the higher frequency of H&Y 
Stages 4 and 5 compared to our study.105   
 
Subjects who presented to this clinic with mild to severe rigidity were less likely to have 
benign progression.  Although the potential association between rigidity and slower 
progression of disease has not been directly investigated, Hoehn and Yahr did report that a 
more benign progression was associated with minimal disabilities.4  Another study also 
found that patients with early onset PD presented more frequently with rigidity.115  Several 
studies investigated differences between tremor dominant PD (TD) and postural instability 
gait difficulty PD (PIGD) or akinetic/rigid PD and found TD to be associated with slower 
progression.94,98  Comparison between these studies and our study is problematic because 
they defined the classification of PD based on a dominant symptom.  The data in this study 
recorded any and all symptoms that were present at baseline, but our analysis did not 
dichotomize subjects as TD versus PIGD.  Louis et al. reported that while the severity of 
bradykinesia, rigidity, and gait disturbances increased over time, tremor remained stable 
leading them to conclude that tremor is relatively independent of disease progression.100  It 
is possible then, given our results, that TD is a sub-group within our benign progression 
category.   
 
Although stroke, family history of PD, ADL, dementia, motor fluctuations, and other 
medications were significant in univariable analysis, they did not remain significant in 
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multivariable analysis even when potential confounding was investigated.  Most of these 
potential prognostic indicators have not been investigated in terms of their association with 
benign progression of disease.  However, two studies did find that those subjects with 
younger age of onset were more likely to develop dyskinesias and fluctuations.38,116   
 
 5.4 Rapid Prog ress ion  
Subjects with rapid progression had shorter disease duration at first visit and had older age 
of onset compared to the not rapid group.  This result was consistent with previous 
studies.91,93,94,99,101,117  The observed age of onset in the rapid group of this study was similar 
to that reported by Birkmayer et al.,99 and Marttila and Rinne.91  Although the reported age 
of onset in the rapid group in the Graham and Sagar study was 11 years younger than our 
study, they still reported that the age of onset in the rapid group was significantly older 
than the two other groups in their study.117  This difference could reflect the smaller sample 
population and the shorter follow-up period of two years as compared to our study.  The 
observed disease duration of this study was similar to that reported by Marttila and Rinne.91  
Other studies have reported disease durations ranging from 4 to 7 years.99, 117  The much 
shorter disease duration of the present study could also reflect the referral pattern to this 
clinic in that the more difficult cases and the more rapidly progressive cases are referred 
sooner.   
 
This current study found that males were less likely to have rapid progression was different 
than previous studies that reported no male-female differences in progression.96,99,113  
Although Birkmayer et al. found no statistical difference between males and females, they 
did report more females in the rapid group than males.99  Our finding also appears to 
contradict the findings of two previous studies where Jankovic and Kapadia reported that 
males progressed at a significantly higher rate than females 94 and Lyons et al. reported that 
males had significantly higher UPDRS motor scores than females.49  Our study appears 
similar to one previous study where women visited the doctor when already in a higher 
H&Y stage than men.105  This could account for the negative association between rapid 
progression and male sex in our study in that more women are reporting to the clinic in a 
later H&Y stage, even though men may be prone to more rapid progression and higher 
reported motor dysfunction.   
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Subjects with mild to severe resting tremor were less likely to have rapid progression.  
Several studies demonstrated a predominance of tremor with slower progression of 
disease.91,94,101  Generally these studies investigated TD versus PIGD or akinetic/rigid 
classifications of PD.  The classifications of PIGD and akinetic/rigid refers to the 
predominance of postural instability and disturbance of gait, or akinesia and rigidity.  
Tremor may be present in subjects with PIGD or akinetic/rigid forms of PD, but it is not 
the predominant symptom.  A recent investigation of clinical heterogeneity found four 
subgroups of PD; young onset, tremor dominant, non-tremor dominant, and rapid.118  The 
non-tremor dominant subgroup was characterized by a mixed motor presentation that 
included tremor (which was not the predominant symptom).  The non-tremor dominant 
subgroup had higher UPDRS scores and more rapid progression than the tremor dominant 
subgroup.  The non-tremor dominant subgroup also had similar UPDRS scores and age of 
onset compare to the rapid group.  Our investigation analyzed any and all symptoms 
present at baseline for associations with rapid progression.  As such, our rapid group could 
reflect a combination of the characteristics of the rapid and non-tremor dominant 
subgroups of the heterogeneity study. 
 
Subjects who presented to this clinic with mild to severe rigidity were more likely to have 
rapid progression.  It has been reported that rapid progression is associated with the most 
severe motor impairment.117  Another study found that rapid progression was associated 
with the predominance of bradykinesia, rigidity, and gait disturbance.101  Several studies, 
that investigated differences between TD and PIGD or Akinetic/Rigid dominant PD, 
found PIGD to be associated with more rapidly progressive disease.94,98  The data in our 
study recorded any and all symptoms that were present at baseline, but analysis did not 
differentiate subjects as TD versus PIGD or akinetic/rigid.  However, our model reported 
the presence of slight resting tremor and mild to severe rigidity.  This mixed motor 
presentation is similar to that reported in a previous investigation of heterogeneity of 
progression.118   
 
Although smoking history, family history of PD, levodopa and other anti-Parkinson 
medication use, motor fluctuations, bradykinesia, and dementia were all significant in 
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univariable analysis they did not remain so during multivariable analysis.  Most other 
studies that investigated these potential prognostic factors did not find any significant 
association with progression of disease.93,99,113,114,117  Louis et al., however did find that ADL 
scores below 70% and the presence of dementia at baseline were predictive of a higher 
total UPDRS score, which is indicative of higher disability and the potential for more rapid 
disease progression.100   
 
 5.5 Compari son o f  the  Benign and Rapid Progress ion 
With respect to age of onset, disease duration, sex and rigidity the benign and rapid models 
are opposite to one another.  For every 10 year increase in the age of onset of disease 
subjects are less likely to have benign progression and more likely to have rapid 
progression.  The longer a subject has disease before visiting this clinic for the first time the 
more likely they are to have benign progression and the less likely they are to have rapid 
progression.  Males were more likely to have benign progression and less likely to have 
rapid progression.  At first visit, if a subject presents with mild to severe rigidity the less 
likely they are to have benign progression and the more likely they are to have rapid 
progression.  Current smokers were more likely to have benign progression.  In rapid 
progression current smokers were less likely to have rapid progression, but the association 
did not remain significant in the presence of other potential variables.  Subjects with mild 
to severe resting tremor were less likely to have rapid progression.  In the analysis of 
benign progression subjects with mild to severe resting tremor were more likely to have 
benign progression, but the association did not remain significant in the presence of other 
potential variables.   
 
 5.6 Strengths  o f this  Study  
The database used in our study was very large and included patients who came from all 
over the province of Saskatchewan. We reported similar age at onset to previous 
community based studies.91,100,105  Previous studies that used clinic databases reported 
longer disease durations and higher frequency of levodopa use than we reported.94,98,100  
This supports our assertion that this study population is a representative community 
sample. 
 
 54 
The database contained a large number of subjects who have been followed for a minimum 
of three years and for as long as 10 years.  Previous progression studies had much smaller 
sample populations, the largest of which was about one third the size of the database used 
in this study.  Many of the previous studies had much shorter follow-up than we had.  
Some of this variation was due to study design such as a five year prospective study.101  
Previous retrospective studies such as Marttila and Rinne did have longer follow-up data, 
but had fewer subjects than our study .91   
 
All subjects in this database were assessed, diagnosed, and treated by one of two 
neurologists, both of whom are movement disorders specialists with an interest in PD.  It 
is generally accepted that ante-mortem clinical diagnosis be performed by a neurologist 
with such experience.9  This limits potential variability in diagnosis and as such less 
potential classification error.   
 
 5.7 Potent ial  Limitat ions  o f  thi s Study  
Some of the independent variables such as age of onset and ADL scale are self-reported 
and as such have inherit bias.  Since age of onset is self reported the calculation of disease 
duration is affected by this self-reported measure.  It is likely that the further one is from 
the first symptom of PD the less accurate the determination of age of onset.  This recall 
bias results in increasing underestimation of disease duration the longer the patient has had 
PD.  This recall bias can then lead to differential misclassification error.  Underestimating 
disease duration would result in underestimated frequency of benign progression; a bias 
toward the null.  The actual OR’s are potentially stronger than observed in this 
investigation. 
 
The use of the H&Y scale could also be problematic in that the key stage for the 
determination of rapid progression is Stage 3.  At this stage the subject has postural 
instability, thus it can be argued that the use of H&Y biases findings by dichotomizing 
results to those with postural instability, the rapid group, and those without postural 
instability, the benign group.  This bias then potentially confounds any real associations of 
the other, potentially significant motor functions.   On the other hand, studies have 
reported that the H&Y is highly correlated with other standardized clinical scales.90  It has 
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also been demonstrated that the H&Y score progresses with PET scan decline in 
dopaminergic function.90  The H&Y is clinically valuable in that it provides an overall 
assessment of clinical severity and functional disability.  Finally, it is a ubiquitous and 
practical assessment scale.90   
 
Levodopa use was mixed in this population.  This has the potential to lead to 
misclassification error because treatment with levodopa attenuates the signs and symptoms 
of PD.  As such, subjects who should be classified as rapid may end up in the average 
group.  This “waters down” the effect causing bias toward the null and underestimating 
any associations observed in the rapid group.  The actual OR’s are potentially stronger than 
what was observed in this investigation. 
   
There is a limit to the generalizability of disease duration.  There is general agreement on 
the starting point of disease duration as the date of first symptom of PD, but the selection 
of the end date of disease duration has varied.  For this study the end-date of disease 
duration was the date of first clinic visit.  Other studies have chosen various end dates such 
as date of visit to outpatients,105 or date of first use of levodopa.93  Disease duration is a 
useful prognostic factor associated with differences in progression of PD for this clinic 
because it still indicates that the longer a subject has had the disease the less likely they are 
to have rapid progression and the more likely they are to have benign progression.   
 
The limitations of using a clinical, retrospective database center around the fact the data 
exists before the questions are asked and as such data is often limited or may not exist for 
specific questions.  One such example is the association of ADL with disease progression.  
Previous studies have demonstrated an association between lower ADL scores and more 
rapid progression of disease.100  In the database used for this study 35% of the ADL scores 
were missing and as such the variable was excluded from analysis.  ADL could be a useful 
clinical tool to aid neurologists in predicting rapid or benign progression in their patients at 
first visit.   Some variables dropped out, while others entered the rapid and benign models 
when ADL was removed.  This indicates that, while ADL may have predictive usefulness, 
it may be confounding other important variables associated with progression of PD.   
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CHAPTER 6 
Conclusion 
 
Prognostic factors measured at first clinic visit can be useful in predicting progression of 
PD.  With more rapid progression closer and more frequent follow-up of patients may be 
required.  The knowledge that certain prognostic factors may be associated with a more 
rapid course could influence the direction of consultation with patients.  Those patients 
identified as potentially having a more rapid course would require appropriate consultation 
that addresses this poorer prognosis.  
 
This study identified potential prognostic factors that can aid clinicians with diagnosis of 
progression.   Further analysis is required to test the hypothesized models for those 
prognostic factors associated with both benign and rapid progression of PD by external 
validation.  However, the model does not answer why there is a difference in the 
progression of disease.  Future research should focus on determining why the significant 
variables in both the rapid and benign models lead to differences in the rate of progression.  
Another focus of future research would be the development of separate male and female 
models of progression.   
 
Currently there are many definitions of progression that use different clinical and/or 
pathological measures.  Some factors associated with progression remain significant 
regardless of the definition used, the major one being age of onset.  Most other potential 
factors have been less consistently reported as significant predictors of progression.  A 
standardized, but clinically expedient definition of progression of PD could be adopted.  
Doing so would likely lend itself to identifying useful clinical and demographic factors 
associated with progression of PD.  On the other hand, the different definitions of 
progression may appropriately account for natural differences in respective populations, 
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which may require different methods of identifying prognostic factors associated with rapid 
and benign progression.   
 
There are challenges with comparing the reported disease durations in previous 
progression studies.  While most agree that disease duration starts from onset of first 
symptom, the end point varies.  In our study the end point for disease duration was the 
date of the first visit to the clinic.  In the Graham and Sagar study, for example the end 
point of disease duration is the date of outpatient visit during the two-year time frame of 
the study.117  As such it is not clear whether this date of outpatient visit reflects the very 
first visit or a follow-up visit.  This would tend to overestimate disease duration.  The 
much shorter disease duration of our study could also be a reflection of the referral pattern 
to this clinic in that the more difficult cases and the more rapidly progressive cases are 
referred sooner to the clinic.   
 
This study investigated the prognostic factors associated with progression of PD.  A 
multivariable logistic regression analysis was conducted for benign progression and rapid 
progression.  The final model for benign progression revealed that subjects with longer 
disease duration, who are males, and are current smokers at first visit were more likely to 
have benign progress while those subjects who had older age of onset, were past smokers, 
had a history of levodopa use, and had mild to severe rigidity at first visit were less likely to 
have benign progression.   The final model for rapid progression revealed that those 
subjects with older age of onset and mild to severe rigidity at first visit were more likely to 
have rapid progression while those who had a shorter disease duration, were males, and 
had mild to severe resting tremor at first visit were less likely to have rapid progression.  
The intention of this study was to identify the clinical factors of patients at first visit to the 
clinic that would help determine how quickly patients progress.  Knowing whether or not a 
patient will progress rapidly or have benign progression of PD can influence the adoption 
of progression specific frequency and detail of follow-up visits. 
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